Data Generated to Date Support Potential for Aclaris’ ATI-2138 to Impact Several Human Inflammatory Diseases - WAYNE, Pa., ...

To present the pioneering concept, Peer and his team encoded the anti-inflammatory protein interleukin-10 into mRNA and ...

Five patients with refractory SLE were treated daily with subcutaneous injections of 1.5 million IU of human IL-2 (aldesleukin) for five consecutive days, and PBMC were analysed by flow cytometry.

Rising air pollution, changes in hormone levels, immune system imbalances and longer life expectancy are increasing the risk ...

UCB, a global biopharmaceutical company, today announced long-term data from the BE HEARD^ trials for BIMZELX®▼ (bimekizumab) in moderate to severe hidradenitis suppurativa (HS). These two-year data, ...

Investment analysts at Leerink Partnrs increased their FY2024 earnings per share (EPS) estimates for Tourmaline Bio in a ...

Silverberg, J.I., Rosmarin, D., Chovatiya, R.  et al.  The regulatory T cell-selective interleukin-2 receptoragonist rezpegaldesleukin in the treatment of inflammatory ...

This provides full disease control: intravenous SPEVIGO treats GPP flares, while subcutaneous SPEVIGO prevents them. 5 ...

创伤、手术和全身性疾病经常导致不可逆的骨质流失，带来严重的痛苦和相当大的经济压力。钛基金属等传统成骨生物材料缺乏有效的成骨能力，需二次手术去除。基于聚合物的植入物和有机/无机杂化材料具备良好的生物相容性，被广泛用于骨软骨修复。然而，这些材料通常机械强 ...

US FDA grants fast track designation to Nektar Therapeutics’ rezpegaldesleukin to treat moderate-to-severe atopic dermatitis: San Francisco Tuesday, February 11, 2025, 16:00 Hrs ...

The following is a summary of “Biomarkers of oxidation, inflammation and intestinal permeability in persons with diabetes ...